Last reviewed · How we verify

gabapentin 600 mg

Viatris Specialty LLC · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

gabapentin 600 mg is a Small molecule drug developed by Viatris Specialty LLC. It is currently FDA-approved.

Gabapentin 600 mg is a small molecule that modulates voltage-gated calcium channels. It has been studied in clinical trials for various conditions, including hip pain, nausea, postoperative pain, and knee osteoarthritis.

At a glance

Generic namegabapentin 600 mg
SponsorViatris Specialty LLC
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about gabapentin 600 mg

What is gabapentin 600 mg?

gabapentin 600 mg is a Small molecule drug developed by Viatris Specialty LLC.

Who makes gabapentin 600 mg?

gabapentin 600 mg is developed and marketed by Viatris Specialty LLC (see full Viatris Specialty LLC pipeline at /company/viatris-specialty-llc).

What development phase is gabapentin 600 mg in?

gabapentin 600 mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing